Tricidine (Trimetazidine) is used for the symptomatic treatment of stable angina pectoris.

Easing the Symptoms of Stable Chest Pain

Tricidine is commonly used to help provide symptomatic relief for conditions involving recurrent chest discomfort, pressure, or tightness. Its use is considered relevant in conditions where symptoms associated with acute or episodic changes require supportive management, which are symptoms that create noticeable physiological strain. This treatment is commonly used to help with providing supportive relief that may help patients cope more steadily with periods of discomfort.

Improving Daily Function and Comfort

The support provided contributes to easing the overall symptom load associated with angina episodes, and this may assist with maintaining a sense of stability when symptoms are more noticeable, thus supporting general well-being during symptomatic phases. By managing the frequency and intensity of chest symptoms, this medication may contribute to improved comfort during periods of heightened symptoms, which is relevant for managing symptoms that interfere with daily functioning.

Regulatory References

1. European Medicines Agency review

Official Eligibility Profile for Tricidine (Trimetazidine)

Regulatory documents strictly define who can and cannot use Tricidine based on specific health conditions, physiological status, and age. The medication is approved exclusively for adults aged 18 and older.

These constraints ensure the medicine is reserved for the approved patient population and prevent use in groups identified by regulators as having high potential for complications or insufficient evidence of safe use.

Interactions with other medicines and products

The official interaction profile for Tricidine is characterized by a limited number of drug-drug interactions, with key constraints centered on pharmacodynamic effects and specific patient conditions, as defined in regulatory documentation.

Documented Drug-Drug Interactions

Co-administration with anti-hypertensive medicines carries a risk of additive pharmacodynamic effects that may increase the potential for low blood pressure (hypotension) or orthostatic hypotension. Furthermore, official regulatory literature notes a restriction on co-administration with Monoamine Oxidase (MAO) Inhibitors, stemming from a lack of formal studies that establish non-interaction.

Exposure and Pharmacokinetic Profile

Official product information indicates that Tricidine does not participate in clinically significant pharmacokinetic interactions involving major enzyme systems like the CYP family or drug transporters. Substances tested, including digoxin, phenazone, and theophylline, showed no effect on the drug’s exposure. The drug’s pharmacokinetic properties are also documented as not being influenced by meals, and no mandatory timing separation rules are listed for its administration.

Population-Specific Constraints

Regulatory documents explicitly state that certain patient populations are expected to experience an increase in drug exposure due to reduced renal clearance. This includes elderly patients (over 75 years old) and individuals with moderate renal impairment (creatinine clearance between 30 and 60 mL/min).

Tricidine (Fusidic Acid) operates through a highly specific pharmacodynamic mechanism centered on the bacterial cell's protein-manufacturing machinery. The molecule selectively targets the Elongation Factor G (EF-G) enzyme, a critical GTPase located on the bacterial ribosome. Fusidic Acid functions as a stabilizing inhibitor, binding to the EF-G-ribosome complex immediately following GTP hydrolysis. This binding locks the enzyme in an inactive state, preventing its release and necessary conformational change. This molecular block effectively halts the translocation step, which is required for the ribosome to move along the messenger RNA (mRNA) and continue building the polypeptide chain. The downstream consequence of this translational arrest is the complete cessation of new protein synthesis and the subsequent arrest of bacterial replication, a phenomenon categorized as bacteriostasis. The mechanism's functional range is constrained by permeability barriers in most Gram-negative bacteria and by the presence of microbial resistance factors, such as FusB/C proteins, which actively override the drug's stabilizing action.

Administration Guidelines

Tricidine (Trimetazidine) is administered via the oral route and is available in different dosage forms, including a 20 mg immediate-release tablet and a 35 mg modified-release tablet. The regimen is determined by the formulation: the 35 mg modified-release tablet is administered twice daily, while the 20 mg immediate-release tablet requires administration three times daily.

All forms must be taken during meals for proper use, and the modified-release tablets must be swallowed whole without being crushed or chewed to preserve their intended release characteristics. If a dose is missed, the recommended practice is to resume treatment normally with the next scheduled dose, without attempting to double the amount to compensate.

The total daily dose must be reduced in adult patients with moderate renal impairment (CrCl 30-60 mL/min); in this scenario, the total dose is reduced to 40 mg per day. Use is not recommended in the pediatric population (under 18 years) due to lack of established data on efficacy and safety. A formal assessment of the treatment benefit must be carried out after three months of continuous use, and the medicine should be discontinued if no response is observed, as part of the established treatment protocol.

Research Evidence / Overview of Studies for Tricidine

The research supporting the uses of Tricidine involves studies on two distinct active components: Fusidic Acid (an antibiotic) and Trimetazidine (a medication studied for symptomatic relief in heart conditions). The evidence landscape for each component was studied for the type of research available, the populations examined, and reported patterns.

Evidence for Use in Symptomatic Stable Angina Pectoris (Trimetazidine)

Research has been studied for Trimetazidine for conditions characterized by outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. The evidence base relies heavily on randomized controlled trials (RCTs) where patients with stable angina pectoris were compared to a placebo or to other established anti-anginal medications. These studies monitored patient-reported outcomes describing perceived discomfort, such as the weekly frequency of angina attacks. Functional assessments were evaluated in a research setting by measuring a person’s ability to perform during an exercise test.

Findings describe patterns observed in the studies, including measurements of the number of weekly angina episodes and changes in exercise tolerance metrics. Comparative evidence is limited for its use as a primary stand-alone treatment, as many trials examined it in combination with other existing therapies.

Evidence for Use in Bacterial Infections of the Skin and Soft Tissues (Fusidic Acid)

Fusidic Acid was studied for its use in resolving bacterial skin and soft tissue infections. The research includes short-term randomized controlled trials (RCTs) that were evaluated in adults and children, comparing Fusidic Acid to other anti-bacterial agents or to non-active controls. The main outcomes research examined were the clinical clearance of the infection (resolution of visible signs) and the microbiological clearance (eradication of the bacteria).

Studies report how symptoms evolved in the observed populations, with findings describing the observed rates of clinical clearance across the studied populations. Research provides context for short-term changes, particularly for superficial infections, but comparative evidence is limited when assessing the full range of alternative topical antibiotics.

What is Still Uncertain About Tricidine’s Research Record

Despite the body of research, several areas are not fully established. For Trimetazidine, the evidence remains primarily focused on symptomatic and functional outcomes related to physical discomfort, and research does not determine whether it affects the long-term prognosis. This information remains insufficient in the current evidence landscape.

For Fusidic Acid, the main area of uncertainty relates to antibiotic resistance. Research describes that patterns of increased resistance over time were monitored in areas of widespread use, and research is ongoing to track this global phenomenon. Evidence quality varies across studies for both components, meaning research provides context but not individual predictions regarding therapeutic response.

Key Studies & References

1. A systematic review and meta-analysis of the efficacy and safety of trimetazidine in patients with stable angina pectoris
2. Trimetazidine - Clinical Trial Results and Cardiovascular Outcomes

Common questions about Tricidine (FAQ)

Q: When will Trimetazidine start to work for my angina?

Trimetazidine has been studied as an add-on therapy for the long-term management of stable angina, according to official information. Clinical data has shown that the medication can improve a person's exercise capacity and decrease the frequency of angina attacks over a course of weeks to a few months. Regulatory documents describe that a formal assessment of the treatment benefit is part of the established protocol after a course of use, such as three months.

Q: Can I take Trimetazidine if I have a severe allergic reaction to one of its excipients (non-active ingredients)?

According to the official product information, Trimetazidine is contraindicated, meaning its use is restricted, if a patient is hypersensitive (allergic) to the active substance or to any of the excipients listed. Excipients are the inactive ingredients, like fillers or coatings, used to make the final medication form. The full product information leaflet contains a complete list of these components.

Q: What is the half-life and clearance of Trimetazidine in the body?

Regulatory documents describe the elimination half-life of Trimetazidine, which is the time it takes for half of the drug to be cleared from the bloodstream. This averages 6 to 8 hours in young, healthy adults, but can be extended to approximately 11 to 12 hours in older adults. The medication is primarily cleared from the body through the kidneys. Official guidelines require caution and dosage adjustments for individuals with reduced kidney function.

Q: What happens if I miss a dose of Trimetazidine or I vomit after taking it?

Official guidance describes managing a missed dose of Trimetazidine by resuming treatment normally with the next scheduled dose, without attempting to take a double amount. If a dose is rejected, such as by vomiting shortly after administration, official instructions state that taking another dose to compensate is not recommended, and to wait for the next scheduled dosing time.

Q: Can Trimetazidine affect my sleep (insomnia or drowsiness)?

Official product labeling lists sleep disorders, including insomnia (difficulty sleeping) and drowsiness (feeling sleepy), as possible side effects. While the reported frequency of these events is generally listed as 'Not known' or 'Uncommon,' they have been noted in safety surveillance reports. The potential for drowsiness or dizziness means these effects may affect the ability to drive or use machinery, according to the safety profile.

Q: What other conditions are considered a contraindication for Trimetazidine use (besides Parkinson's and renal impairment)?

The official eligibility profile lists several conditions that strictly contraindicate the use of Trimetazidine. In addition to established Parkinson's disease and severe renal impairment, these include hypersensitivity to the drug, other related movement disorders such as tremors, and restless leg syndrome. Contraindications are specific conditions where regulatory documents restrict the use of the drug due to the potential for complications.

Q: Is there a Black Box Warning for Trimetazidine?

Regulatory documents do not specify a U.S. FDA Black Box Warning for Trimetazidine. However, the regulatory documents include explicit Warnings and Precautions related to its use, even without a Black Box Warning designation. These warnings advise against prescribing the medicine to patients with Parkinson's disease or other movement disorders, as the drug can cause or worsen these neurological symptoms.

Q: Why are there different tablet strengths of Trimetazidine (e.g., 20mg and 35mg)?

The different strengths and formulations of Trimetazidine (such as the 20mg immediate-release and 35mg modified-release tablets) are designed to support the various prescribed daily regimens. For example, a lower strength might be explicitly recommended for specific patient populations, such as those with moderate renal impairment, where a reduction in the total daily dose is indicated.

Q: How long do I need to use Fusidic Acid before my skin infection clears up?

Regulatory guidance on the use of Fusidic Acid for bacterial skin infections indicates that the treatment duration is typically short. For topical use, the duration is commonly 5 to 7 days. Oral treatments may range from 5 to 10 days, but official instructions describe that the treatment duration is not recommended to exceed 14 continuous days, as this measure is intended to help manage the risk of antibiotic resistance.

How to Store and Dispose of Tricidine?

Tricidine (Trimetazidine) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Requirements

The medicine must be stored at a temperature not exceeding 30°C to preserve product quality. It is mandatory to keep this medicine out of the sight and reach of children to prevent accidental exposure or ingestion. The product should be kept in its primary packaging, such as the original blister pack, for protection.

Disposal Instructions

Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Unused or expired medicines should not be discarded in wastewater or household trash, unless specific local guidelines permit.